In what may be described as a decisive move, Senator Ruben Gallego (D-AZ) has put his support behind a new bill aimed at confronting the mounting cost of prescription medications for Americans with private insurance. The proposed "Capping Prescription Costs Act" aims to set an annual out-of-pocket limit at $2,000 for individuals and $4,000 for families, a significant measure in light of the financial strain many face when attempting to purchase necessary medications.
Senator Gallego expressed his motivations directly, "No one should have to choose between putting food on the table and filling a prescription," as per the official press release from Senator Gallego office. He detailed the difficult choices made by Arizonans due to prohibitive costs, including skipping doses or halving pills, nuances that underline the urgency of the bill. He emphasized his stance, "I’m proud to support this bill to put a cap on out-of-pocket costs and make lifesaving medicine more affordable for every family."
The initiative comes in response to a backdrop where over 60 percent of American adults take at least one prescription drug, yet the country grapples with higher drug prices compared to other nations. This disparity leads to troubling compromises in healthcare, with a study cited in the bill's text that 31 percent of patients have avoided taking their medications as prescribed due to the associated costs. The intended cap's impact is widespread, projected to affect all 173 million Americans with private health insurance.
The full text of the legislation, aimed at systemic change within the healthcare landscape, is accessible through an online portal provided by Senator Gallego's office. His efforts extend beyond this act, including calls for preemptive measures against Medicare Part D premium hikes and previous backing of the Lower Drug Costs for Families Act, which seeks to penalize price hikes exceeding inflation rates.
Gallego's legislative history shows a consistent pattern of advocating for affordability and transparency in drug pricing – from his attempts to regulate PBMs to his support for the PATIENT Act.
